title: Atrial natriuretic peptide modulates alveolar type 2 cell adenylyl and guanylyl cyclases and inhibits surfactant secretion.
abstract: Alveolar epithelial type 2 (T2) cells isolated from the lungs of adult rats responded to exogenous atrial natriuretic peptide (ANP) by two signalling mechanisms. First, ANP induced a dose-dependent reduction of ligand-stimulated adenylyl cyclase activity and cAMP accumulation. This effect was inhibited by the addition of GDPbetaS or by pretreatment with pertussis toxin (PT), consistent with mediation by a Gi protein(s). PT-catalyzed [32P]ADP-ribosylation, immunoblots with specific antisera, and Northern blot analysis demonstrated that T2 cells contain the G-proteins Gi2 and Gi3 which could transduce this signal. ANP also promoted PT-insensitive, dose-dependent accumulation of cGMP, consistent with activation of a receptor guanylyl cyclase. Isoproterenol-stimulated phosphatidylcholine secretion was markedly attenuated by ANP, and this effect was inhibited by PT pretreatment, consistent with mediation by a Gi protein(s). These data indicate that in addition to the lung being a major clearance organ for circulating ANP, lung parenchymal cells are targets of ANP action.
authors.affiliation: Pulmonary Center and Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA.
authors.forename: M P
authors.initials: MP
authors.lastname: Panchenko
authors.forename: M
authors.initials: M
authors.lastname: Joyce-Brady
authors.forename: M G
authors.initials: MG
authors.lastname: Starikova
authors.forename: S M
authors.initials: SM
authors.lastname: Oakes
authors.forename: R
authors.initials: R
authors.lastname: Adachi
authors.forename: J S
authors.initials: JS
authors.lastname: Brody
authors.forename: B F
authors.initials: BF
authors.lastname: Dickey
mesh_terms: D037361:Adenylate Cyclase Toxin; D000262:Adenylyl Cyclases / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000494:pharmacology*; D001993:Bronchodilator Agents / Q000494:pharmacology; D002462:Cell Membrane / Q000187:drug effects / Q000201:enzymology; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000166:cytology* / Q000187:drug effects* / Q000201:enzymology; D019204:GTP-Binding Proteins / Q000187:drug effects / Q000378:metabolism; D006162:Guanylate Cyclase / Q000187:drug effects* / Q000378:metabolism; D007545:Isoproterenol / Q000494:pharmacology; D008024:Ligands; D037342:Pertussis Toxin; D010713:Phosphatidylcholines / Q000378:metabolism; D011650:Pulmonary Alveoli / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology; D051381:Rats; D013501:Surface-Active Agents / Q000378:metabolism*; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
chemical_list: D037361:Adenylate Cyclase Toxin; D001993:Bronchodilator Agents; D008024:Ligands; D010713:Phosphatidylcholines; D013501:Surface-Active Agents; D010566:Virulence Factors, Bordetella; D009320:Atrial Natriuretic Factor; D000242:Cyclic AMP; D037342:Pertussis Toxin; D019204:GTP-Binding Proteins; D000262:Adenylyl Cyclases; D006162:Guanylate Cyclase; D006152:Cyclic GMP; D007545:Isoproterenol